The Challenging Decision to Commence Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer NAC Hormone-positive Breast cancer

Sanambar Sadighi (1)
(1) Tehran University of Medical Sciences, Iran, Islamic Republic of

Abstract

N/A

Full text article

Generated from XML file

References

Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008 Feb 10;26(5):814-9. doi: 10.1200/JCO.2007.15.3510.

Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer 2004; 100:2512. doi: 10.1002/cncr.20298.

Mamtani A, Barrio AV, King TA, Van Zee KJ, Plitas G, Pilewskie M, et al. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Ann Surg Oncol. 2016 Oct;23(11):3467-3474. doi: 10.1245/s10434-016-5246-8.

Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994; 30A:645. doi: 10.1016/0959-8049(94)90537-1.

Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007;:CD005002.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 2018; 19:27.

Kim HS, Yoo TK, Park WC, Chae BJ. Potential benefits of neoadjuvant chemotherapy in clinically node-positive luminal subtype breast cancer. 2019;22(3):412-24. doi:10.4048/jbc.2019.22.e35.

Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Updated efficacy and Ki-67 analysis from the monarchE study. Ann. Oncol. 2021, 32, 1571–1581.

Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana, L, et al. Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. Cancers 2022, 14, 1898.

Bozdogan A, Emiroglu S, Abuaisha A, Basar OD. Risk factors of response to neoadjuvant chemotherapy in patients with luminal (HER2 negative) breast cancer: ROC curve and logistic regression model results. Archives breast cancer. 2024;11(1):67-75. doi: 10.32768/abc.202411167.74

Höller A, Nguyen-Sträuli BN, Frauchiger-Heuer H, Ring A. Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now? Breast Cancer: Targets and Therapy. doi: 10.2147/BCTT.S340741

Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18:297–312. doi:10.1038/s41571-020-00457-x

Carlo Pescia C , Guerini-Rocco E, Viale G, Fusco N. Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies. Cancers 2023, 15, 5430. doi: 10.3390/cancers15225430.

Authors

Sanambar Sadighi
Sadighi.sanambar@gmail.com (Primary Contact)
1.
Sadighi S. The Challenging Decision to Commence Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer: NAC Hormone-positive Breast cancer. Arch Breast Cancer [Internet]. 2024 May 1 [cited 2024 Jun. 16];11(2):106-7. Available from: https://www.archbreastcancer.com/index.php/abc/article/view/882

Article Details